QuidelOrtho vs Bio-Techne
QDEL and TECH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How QDEL and TECH compare
Bio-Techne is the larger company, worth 13 times as much as QuidelOrtho ($11.4B against $909M).
Bio-Techne grew revenue faster over the last twelve months (−0.38% versus −2.5% for QuidelOrtho).
Bio-Techne pays a dividend yielding 0.44%; QuidelOrtho does not pay one.
Bio-Techne scores higher on the StockData Score (12 against 6 for QuidelOrtho), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | QDEL | TECH |
|---|---|---|
| Size and price | ||
| Market cap | $909M | $11.4B |
| Share price | $13.25 | $72.66 |
| Change, 1 year | −52.6% | 17.2% |
| Change, 5 years | −89.1% | −41.6% |
| Beta (5Y) | 0.85 | 1.08 |
| Employees | 6,500 | 3,000 |
| StockData Score | ||
| Total score | 6 | 12 (better) |
| Valuation score | 3 (better) | 2 |
| Growth score | 0 | 1 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 62.6× |
| P/S | 0.3× (better) | 9.4× |
| P/B | 0.5× (better) | 5.4× |
| EV/EBITDA | – | 32.4× |
| P/FCF | – | 43.3× |
| FCF yield | −23.2% | 2.3% (better) |
| Fair value | $84.25 | $52.72 |
| Margin of safety | 84.3% (better) | −37.8% |
| Growth | ||
| Revenue growth (TTM) | −2.5% | −0.38% (better) |
| Revenue growth, 5Y average | 10.4% (better) | 5.5% |
| EPS growth (TTM) | – | 152% |
| EPS growth, 5Y average | – | 5.9% |
| Profitability | ||
| Gross margin | 44.6% | 65.8% (better) |
| Operating margin | −30.8% | 20.7% (better) |
| Net margin | −39.2% | – |
| FCF margin | −7.9% | 21.7% (better) |
| Return on equity | −45.9% | – |
| Return on invested capital | −13.3% | 9.2% (better) |
| Financial health | ||
| Debt / equity | 1.63 | 0.09 (better) |
| Net debt / EBITDA | – | −0.19 |
| Interest coverage | −4.1× | 26.2× (better) |
| Current ratio | 1.39 | 4.55 (better) |
| Altman Z-score | −0.08 | 15.97 (better) |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Dividend yield | – | 0.44% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | −0.57% | 0.37% (better) |
| Shareholder yield | −0.57% | 0.81% (better) |
| Ownership | ||
| Held by institutions | 121% | 112% |
| Held by insiders | 43.4% | 0.35% |
| Insider net buying, 12 months | $1.2M (better) | −$437K |
| Superinvestors holding | – | 4 |
| Short interest, % of float | 38.5% | 4.7% |
Go deeper
- QDEL stock overview
- QDEL income statement
- QDEL valuation and score
- TECH stock overview
- TECH income statement
- TECH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.